View
Page
finnCap's note from this morning: "Premaitha is a molecular diagnostics company that has developed and launched a non-invasive prenatal test (NIPT), targeted initially at ex-US markets; the company is primarily products-based, addressing the needs of its laboratory customers. Differentiated from other NIPTs by a faster turnaround time, a reduced need to re-run tests (failure rate), the fact that the test is CE marked and that it matches the specifications of National screening programmes, Premaitha is well placed to capitalise on an addressable market worth $7.5-20.0bn. First-year revenues of c£2.5m are indicative of early traction in a European market that is underpenetrated compared with the US (c1.4% vs 25%). We..." From Research Tree
Latest from the Community...
Latest from the Community...
Latest from the Community...
